TIA supports access to production of of viral vectors (inc. lentivirus, adenovirus and adeno-associated virus) to support preclinical proof-of-concept work to develop strategies for targeted delivery of advanced cell and gene therapies to specific tissues. Expertise includes capsid optimisation to improve tissue specificity, and developing improved vectors leading to better titres. The quality of production is controlled by extensive QA procedures.